AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15840666
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline placebo (NS) with loop diuretic (LD)
Trial: 31163106
Drug: Sertraline 50
RxNorm normalized name: sertraline 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline 50 mg/d and EPA 2 g/d
Trial: 31163106
Drug: Sertraline 50
RxNorm normalized name: sertraline 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline 50 mg/d and corn oil placebo
Trial: 26220802
Drug: Daily electronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily electronic self-monitoring using smartphones for 6 months
Trial: 21704290
Drug: Iodine-based skin
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodine-based skin preparations followed by a cyanoacrylate-based skin sealant
Trial: 21704290
Drug: Skin preparations
RxNorm normalized name: human skin preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin preparations alone
Trial: 19254970
Drug: Volume-targeted ventilation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume-targeted ventilation at 4 mL/kg
Trial: 19254970
Drug: Volume-targeted ventilation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume-targeted ventilation at 5 mL/kg
Trial: 19254970
Drug: Volume-targeted ventilation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume-targeted ventilation at 6 mL/kg
Trial: 11291971
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C 1,000 mg
Trial: 11291971
Drug: 400 gm
RxNorm normalized name: vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 gm of fruit daily
Trial: 9253564
Drug: Patient controlled
RxNorm normalized name: PATIENT CONTROLLED ANALGESIA VIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient controlled analgesia with morphine
Trial: 9253564
Drug: Remifentanil post-operative
RxNorm normalized name: Sx1 Medicated Post-Operative System KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil post-operative infusion
Trial: 3755348
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine 0.8 mg
Trial: 24214189
Drug: Topiroxostat 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiroxostat 60 mg
Trial: 30218318
Drug: Self-reported monthly
RxNorm normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported monthly non-adherence (ring ever out, out for ≥12 hours)
Trial: 30218318
Drug: Composite measure
RxNorm normalized name: DRESSING,COMPOSITE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Composite measure of non-adherence (plasma DPV value ≤95 pg/ml and residual ring ≥23.5 mg)
Trial: 26908964
Drug: Delamanid, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delamanid, a new drug for the treatment of multidrug-resistant tuberculosis.
Trial: 17492425
Drug: Moderate alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moderate alcohol consumption (100 ml whisky, approximately 32 g alcohol daily for 4 weeks)
Trial: 15726874
Drug: Talinolol 200
RxNorm normalized name: talinolol
DrugBank: Talinolol (DB11770)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talinolol 200 mg once daily
Trial: 15726874
Drug: Talinolol 300
RxNorm normalized name: talinolol
DrugBank: Talinolol (DB11770)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talinolol 300 mg once daily
Trial: 15726874
Drug: Talinolol 100
RxNorm normalized name: talinolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talinolol 100 mg once daily
Trial: 2532533
Drug: Mivacurium infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mivacurium infusion during halothane anaesthesia
Trial: 2532533
Drug: Mivacurium infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mivacurium infusion during opioid anaesthesia
Trial: 2532533
Drug: Recovery index
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recovery index for all patients after discontinuing the infusion
Trial: 6405427
Drug: Amylobarbitone sodium
RxNorm normalized name: Amylobarbitone sodium
DrugBank: Amobarbital (DB01351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amylobarbitone sodium (200 mg)
Trial: 29036257
Drug: Topical DNA
RxNorm normalized name: Toxoplasma gondii DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical DNA repair enzyme lotion applied twice daily for 8 weeks
Trial: 29036257
Drug: Placebo (Eucerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Eucerin Professional lotion) applied twice daily for 8 weeks
Trial: 23333022
Drug: Daily Cone
RxNorm normalized name: Pinus strobus cone extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Cone Beam Computed Tomography (CBCT)
Trial: 23333022
Drug: Daily Electronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Electronic Portal Imaging with Fiducial Markers (EPI-FM)
Trial: 23333022
Drug: Weekly controls
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly controls (CBCT and EPI-FM)
Trial: 21256073
Drug: Specific treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific treatment based on the Movement System Impairment (MSI) model
Trial: 21256073
Drug: Non-Specific treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-Specific treatment
Trial: 18175830
Drug: Local phototherapy
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local phototherapy (one-time treatment)
Trial: 15682975
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of rifampicin for chemoprophylaxis
Trial: 10510918
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg morphine sulfate (MS)
Trial: 10510918
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg ketorolac tromethamine (KT)
Trial: 10510918
Drug: Topical 2.5%
RxNorm normalized name: menthol topical 2.5% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 2.5% lidocaine/prilocaine gel (Emla)
Trial: 1883120
Drug: Enalapril plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril plus conventional antihypertensives
Trial: 1883120
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus conventional antihypertensives
Trial: 26724841
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg of dutasteride
Trial: 24630937
Drug: Perceived benefits
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perceived benefits of GM (e.g. reduced threats to crops and a more secure food supply)
Trial: 22466467
Drug: 0.75% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75% ropivacaine with 75 IU of hyaluronidase as peribulbar injection of 5 mL before surgery
Trial: 22466467
Drug: 0.75% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75% ropivacaine with 75 IU of hyaluronidase as peribulbar injection of 1 mL or 3 mL before surgery
Trial: 22466467
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (30 patients without any additional analgesic treatment)
Trial: 22466467
Drug: 0.75% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75% ropivacaine with 75 IU of hyaluronidase as peribulbar injection of 5 mL after surgery
Trial: 18039077
Drug: High-loading dose
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-loading dose regimen of liposomal amphotericin B (L‐AMB)
Trial: 18039077
Drug: Standard dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosing regimen of liposomal amphotericin B (L‐AMB)
Trial: 12124952
Drug: Intra-atrial infusion
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-atrial infusion of heparin and tissue plasminogen activator (t-PA)
Trial: 12124952
Drug: Heparin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin and streptokinase
Trial: 7483799
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of oral poliomyelitis (OPV) and diphtheria and tetanus (DTV) vaccines
Trial: 7483799
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of OPV and DTV vaccines plus recombinant hepatitis B vaccine (HBV)
Trial: 7483799
Drug: HBV recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBV recombinant vaccine alone
Trial: 16775229
Drug: Ibuprofen 200
RxNorm normalized name: ibuprofen 200 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 200 to 400 mg
Trial: 7821102
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg erythromycin
Trial: 11293641
Drug: 325 mg
RxNorm normalized name: lysine 325 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 325 mg co-amoxiclav (250 mg amoxicillin and 125 mg clavulanic acid)
Trial: 11293641
Drug: both antibiotics
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: both antibiotics (erythromycin and co-amoxiclav)
Trial: 18603947
Drug: Trabeculectomy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabeculectomy with combination of permanent and releasable scleral flap sutures (Group B)
Trial: 12585979
Drug: HSV-2 vaccine
RxNorm normalized name: HSV-2 theracine
DrugBank: HSV-2 theracine (DB05811)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSV-2 vaccine
Trial: 1394809
Drug: Intravesical instillations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical instillations of Adriamycin (ADM) at 20 mg/40 ml physiological saline for 2 years after TUR (Group A)
Trial: 1394809
Drug: Intravesical instillations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical instillations of Adriamycin (ADM) at 20 mg/40 ml physiological saline for 2 weeks before TUR (Group B)
Trial: 28965100
Drug: Oral resveratrol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral resveratrol, 40 mg (two caplets) two times per day for 1 week, then 20 mg (one caplet) two times per day for a total of 6 months
Trial: 28965100
Drug: Oral resveratrol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral resveratrol
Trial: 23948785
Drug: Acetyl-L-carnitine (1000-3000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetyl-L-carnitine (1000-3000 mg daily) plus α-lipoic acid (600-1800 mg daily)
Trial: 21615419
Drug: Testosterone (1000mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone (1000mg intramuscular long-acting testosterone undecanoate)
Trial: 21615419
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone (33μg)
Trial: 18329882
Drug: Porous coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Porous coated prosthesis with solution-deposited HA
Trial: 15552357
Drug: Cues receiving
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cues receiving strong inputs from other associates (e.g., car)
Trial: 11172852
Drug: Tibolone plus
RxNorm normalized name: TIBOLONE
DrugBank: Tibolone (DB09070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone plus GnRH analogue (leuprolide acetate and iron tablets)
Trial: 11172852
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus GnRH analogue (leuprolide acetate and iron tablets)
Trial: 11172852
Drug: GnRH analogue
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH analogue (leuprolide acetate and iron tablets)
Trial: 7837950
Drug: Hypocaloric diet
RxNorm normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypocaloric diet (HD) therapy
Trial: 3287534
Drug: Aminophylline (1-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline (1-2 mg/kg)
Trial: 29668352
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (fluticasone furoate 100 μg, umeclidinium 62.5 μg, vilanterol 25 μg)
Trial: 29668352
Drug: Fluticasone furoate-vilanterol
RxNorm normalized name: Fluticasone Furoate-Vilanterol Ellipta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone furoate-vilanterol (100 μg and 25 μg)
Trial: 29668352
Drug: Umeclidinium-vilanterol (62.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Umeclidinium-vilanterol (62.5 μg and 25 μg)
Trial: 21105284
Drug: Bepotastine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bepotastine (10 mg)
Trial: 18410464
Drug: Diphenhydramine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenhydramine (30 mg)
Trial: 16822134
Drug: Gaze direction
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gaze direction and concurrent auditory temporal information
Trial: 12798894
Drug: P1 medium
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P1 medium supplemented with 0.5 mg/mL hyaluronic acid for 5‐10 min before intrauterine transfer
Trial: 11004052
Drug: Hyaluronidase 3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyaluronidase 3.75 IU/mL
Trial: 11004052
Drug: Hyaluronidase 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyaluronidase 7.5 IU/mL
Trial: 8770965
Drug: Enalaprilat (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalaprilat (10 mg i.v.)
Trial: 8770965
Drug: Exogenous angiotensin
RxNorm normalized name: Angiotensin 1-7
DrugBank: Angiotensin 1-7 (DB11720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exogenous angiotensin II infusion
Trial: 1628410
Drug: Nicardipine slow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine slow release 40 mg twice daily
Trial: 31606364
Drug: Mineralocorticoid antagonists
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Mineralocorticoid antagonists (MRAs) therapy maintained or increased during hospitalization
Trial: 31606364
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) maintained or increased during hospitalization
Trial: 31606364
Drug: Down-titration of
RxNorm normalized name: Kool-Down
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Down-titration of MRAs during hospitalization
Trial: 30307304
Drug: L-arginine (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (7 g)
Trial: 30307304
Drug: L-arginine (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (7 g) alone (L-ARG)
Trial: 30307304
Drug: EX-LARG (L-arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EX-LARG (L-arginine + exercise)
Trial: 25228130
Drug: Continuous insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous insulin infusion during surgery (n = 33)
Trial: 22410137
Drug: 4-month daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-month daily rifampicin regimen (4R); n = 190
Trial: 22410137
Drug: 6-month daily
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month daily isoniazid regimen (6H); n = 183
Trial: 19111163
Drug: Subcutaneous immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous immunotherapy (SCIT) with alum-formulated recombinant human GAD65
Trial: 15879822
Drug: Active electromagnetic
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active electromagnetic therapy (15 minutes at 10 Hz followed by 15 minutes at 50 Hz, twice weekly for 4 weeks)
Trial: 12743130
Drug: Cisplatin-based intraperitoneal
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-based intraperitoneal treatment
Trial: 8867677
Drug: Monthly replacement
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly replacement schedule
Trial: 8867677
Drug: Three monthly
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three monthly replacement schedule
Trial: 3986081
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg doses of caffeine as an aqueous oral solution
Trial: 3986081
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg doses of caffeine as an intravenous infusion
Trial: 25917561
Drug: Prasugrel (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel (60 mg)
Trial: 25917561
Drug: Clopidogrel (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (600 mg)
Trial: 20862933
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with speech therapy
Trial: 20862933
Drug: Speech therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Speech therapy only (Control)
Trial: 22795211
Drug: d-serine 2
RxNorm normalized name: D-Serine
DrugBank: D-Serine (DB03929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-serine 2 g/d
Trial: 12704001
Drug: CAF regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAF regimen (Cytoxan 600 mg/m(2), Adriamycin 60 mg/m(2), 5‐FU 600 mg/m(2))
Trial: 12704001
Drug: TP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TP regimen (paclitaxel 135 mg/m(2), cisplatin 60 mg/m(2))
Trial: 8607102
Drug: Intermittent regional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent regional therapy with 20 mg rt-PA for 4 h each day
Trial: 8607102
Drug: Systemic thrombolytic
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic thrombolytic therapy with 20 mg rt-PA for 4 h each day
Trial: 8607102
Drug: Both interventions
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both interventions (intermittent regional and systemic thrombolytic therapy)
Trial: 1103743
Drug: Topically applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topically applied griseofulvin in alcohol solution
Trial: 27577562
Drug: Mentalization-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mentalization-based treatment (MBT)
Trial: 21226754
Drug: Nurse-administered minimal
RxNorm normalized name: Centipeda minima whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse-administered minimal psychological intervention
Trial: 16635651
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (drug-free subjects)
Trial: 1358004
Drug: Atracurium 0.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium 0.50 mg.kg‐1
Trial: 1358004
Drug: Vecuronium 0.10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.10 mg.kg‐1
Trial: 25258045
Drug: Spinal manipulative
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal manipulative therapy and exercise interventions
Trial: 23517382
Drug: Autologous noncultured
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous noncultured epidermal cell suspension (NCES)
Trial: 18346604
Drug: Bupivacaine 0.125%
RxNorm normalized name: BUPIVACAINE 0.125%/NS INJ 250ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.125% + morphine
Trial: 18346604
Drug: Ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2% + morphine
Trial: 15892618
Drug: Bevacizumab (Avastin)
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab (Avastin) in combination with gemcitabine for pancreatic cancer
Trial: 12009370
Drug: One transcervical
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One transcervical insertion of 252 mg of quinacrine
Trial: 12009370
Drug: Two transcervical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two transcervical insertions of 252 mg of quinacrine
Trial: 7775186
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg meperidine with 25 mg promethazine IM
Trial: 7775186
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg dihydroergotamine with 10 mg metoclopramide IV
Trial: 2190629
Drug: Cadralazine 10
RxNorm normalized name: cadralazine
DrugBank: Cadralazine (DB13452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cadralazine 10 mg oral dose
Trial: 30025177
Drug: 4.5 g
RxNorm normalized name: Zosyn 4.5 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.5 g of intravenous MgSO4 (low-dose group)